Medincell to Participate in Two Investor Conferences in November
Medincell, a biopharmaceutical company based in Montpellier, announces that its executives will participate in two investor conferences scheduled for November 2025, according to a press release.
Medincell, which specializes in the development of long-acting injectable drugs, will attend the UBS Global Healthcare Conference and the Stifel Healthcare Conference in November. This will provide an opportunity for Dr. Grace Kim, Chief Strategy Officer, and Dr. Richard Malamut, Medical Director, to present the company's strategy and recent developments, as stated in the press release.
Innovative Drug Release Technology
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The company utilizes its proprietary BEPO technology to control the release of drugs at therapeutic levels for extended periods. The first treatment using this technology, aimed at schizophrenia, was approved by the FDA in 2023 and is distributed in the United States by Teva under the name UZEDY.
Collaborations and Company Growth
Medincell collaborates with leading pharmaceutical companies and foundations to develop new treatment options. The company, which employs over 140 people from 25 different nationalities, continues to expand its pipeline of drug candidates at various stages of development.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
